Modulation of microrna-194 and cell migration by her2-targeting trastuzumab in breast cancer

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Le, Xiao Feng ^a   Almeida, Maria I ^a,b   Mao, Weiqun ^a   Spizzo, Riccardo ^a   Rossi, Simona ^a,c   Nicoloso, Milena S ^a   Zhang, Shu ^a   Wu, Yun ^a   Calin, George A ^a   Bast, Robert C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MINHO   (Portugal)

^c SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN G; LUCIFERASE; MICRORNA; MICRORNA 194; TALIN; TALIN2; TRASTUZUMAB; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REPORTER GENE;

EID: 84864072975     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041170     Document Type: Article

References (69)

1. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, et al. (1989) p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9: 1165-1172.
2. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648.
3. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
4. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, et al. (2001) Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722-2730.
5. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, et al. (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595.
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
7. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, et al. (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808.
8. Hortobagyi GN, Perez EA, (2001) Integration of trastuzumab into adjuvant systemic therapy of breast cancer: ongoing and planned clinical trials. Semin Oncol 28: 41-46.
9. Cardoso F, Piccart MJ, Durbecq V, Di Leo A, (2002) Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer 3: 247-257; discussion 258-249.
10. Nahta R, Esteva FJ, (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8: 215.
11. Lane HA, Motoyama AB, Beuvink I, Hynes NE, (2001) Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol 12: S21-22.
12. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, et al. (2006) Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle 5: 1654-1661.
13. Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, et al. (2003) The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278: 23441-23450.
14. Le XF, Lammayot A, Gold D, Lu Y, Mao W, et al. (2005) Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280: 2092-2104.
15. Le XF, McWatters A, Wiener J, Wu JY, Mills GB, et al. (2000) Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 6: 260-270.
16. Le XF, Pruefer F, Bast RC Jr, (2005) HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 4: 87-95.
17. Le XF, Vadlamudi R, McWatters A, Bae DS, Mills GB, et al. (2000) Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Res 60: 3522-3531.
18. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, et al. (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440.
19. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, et al. (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132-4141.
20. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.
21. Pegram MD, Slamon DJ, (1999) Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity. Semin Oncol 26: 89-95.
22. Wen XF, Yang G, Mao W, Thornton A, Liu J, et al. (2006) HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25: 6986-6996.
23. Guler M, Yilmaz T, Ozercan I, Elkiran T, (2009) The inhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol 147: 703-708 e702.
24. Le XF, Mao W, Lu C, Thornton A, Heymach JV, et al. (2008) Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle 7: 3747-3758.
25. Klos KS, Zhou X, Lee S, Zhang L, Yang W, et al. (2003) Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98: 1377-1385.
26. Koukourakis MI, Simopoulos C, Polychronidis A, Perente S, Botaitis S, et al. (2003) The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status? Anticancer Res 23: 1673-1680.
27. Izumi Y, Xu L, Di Tomaso E, Fukumura D, Jain RK, (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280.
28. Baselga J, Albanell J, (2001) Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12: S35-41.
29. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, et al. (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749.
30. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, et al. (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259-267.
31. Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, et al. (2008) Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 6: 25.
32. Kono K, Takahashi A, Ichihara F, Sugai H, Fujii H, et al. (2002) Impaired antibody-dependent cellular cytotoxicity mediated by herceptin in patients with gastric cancer. Cancer Res 62: 5813-5817.
33. Lee S, Yang W, Lan KH, Sellappan S, Klos K, et al. (2002) Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 62: 5703-5710.
34. Henson ES, Hu X, Gibson SB, (2006) Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 12: 845-853.
35. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, et al. (2005) Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 23: 2460-2468.
36. Ambros V, (2001) microRNAs: tiny regulators with great potential. Cell 107: 823-826.
37. He L, Hannon GJ, (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531.
38. Spizzo R, Nicoloso MS, Croce CM, Calin GA, (2009) SnapShot: MicroRNAs in Cancer. Cell 137: 586-586 e581.
39. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA, (2009) MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293-302.
40. Le XF, Merchant O, Bast RC, Calin GA, (2010) The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron 3: 137-147.
41. Hummel R, Hussey DJ, Haier J, (2010) MicroRNAs: predictors and modifiers of chemo- and radiotherapy in different tumour types. Eur J Cancer 46: 298-311.
42. Rukov JL, Shomron N, (2011) MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. Trends Mol Med 17: 412-423.
43. Allen KE, Weiss GJ, (2010) Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther 9: 3126-3136.
44. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, et al. (2002) Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99: 15524-15529.
45. Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC Jr, (2007) Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Mol Cancer Ther 6: 2843-2857.
46. Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr, (2010) Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 116: 4980-4990.
47. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, et al. (2007) MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A 104: 15805-15810.
48. Burridge K, Connell L, (1983) Talin: a cytoskeletal component concentrated in adhesion plaques and other sites of actin-membrane interaction. Cell Motil 3: 405-417.
49. Burridge K, Mangeat P, (1984) An interaction between vinculin and talin. Nature 308: 744-746.
50. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435: 834-838.
51. Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, et al. (2004) MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res 14: 2486-2494.
52. Hino K, Fukao T, Watanabe M, (2007) Regulatory interaction of HNF1-alpha to microRNA-194 gene during intestinal epithelial cell differentiation. Nucleic Acids Symp Ser (Oxf) pp. 415-416.
53. Hino K, Tsuchiya K, Fukao T, Kiga K, Okamoto R, et al. (2008) Inducible expression of microRNA-194 is regulated by HNF-1alpha during intestinal epithelial cell differentiation. Rna 14: 1433-1442.
54. Meng Z, Fu X, Chen X, Zeng S, Tian Y, et al. (2010) miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology 52: 2148-2157.
55. Braun CJ, Zhang X, Savelyeva I, Wolff S, Moll UM, et al. (2008) p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res 68: 10094-10104.
56. Song Y, Zhao F, Wang Z, Liu Z, Chiang Y, et al. (2011) Inverse Association between miR-194 Expression and Tumor Invasion in Gastric Cancer. Ann Surg Oncol.
57. Georges SA, Biery MC, Kim SY, Schelter JM, Guo J, et al. (2008) Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. Cancer Res 68: 10105-10112.
58. Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, et al. (2011) MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 10: 99.
59. Franco-Cea A, Ellis SJ, Fairchild MJ, Yuan L, Cheung TY, et al. (2010) Distinct developmental roles for direct and indirect talin-mediated linkage to actin. Dev Biol 345: 64-77.
60. Moser M, Legate KR, Zent R, Fassler R, (2009) The tail of integrins, talin, and kindlins. Science 324: 895-899.
61. Monkley SJ, Pritchard CA, Critchley DR, (2001) Analysis of the mammalian talin2 gene TLN2. Biochem Biophys Res Commun 286: 880-885.
62. Di Paolo G, Pellegrini L, Letinic K, Cestra G, Zoncu R, et al. (2002) Recruitment and regulation of phosphatidylinositol phosphate kinase type 1 gamma by the FERM domain of talin. Nature 420: 85-89.
63. Priddle H, Hemmings L, Monkley S, Woods A, Patel B, et al. (1998) Disruption of the talin gene compromises focal adhesion assembly in undifferentiated but not differentiated embryonic stem cells. J Cell Biol 142: 1121-1133.
64. Zhang X, Jiang G, Cai Y, Monkley SJ, Critchley DR, et al. (2008) Talin depletion reveals independence of initial cell spreading from integrin activation and traction. Nat Cell Biol 10: 1062-1068.
65. Monkley SJ, Kostourou V, Spence L, Petrich B, Coleman S, et al. (2010) Endothelial cell talin1 is essential for embryonic angiogenesis. Dev Biol 349: 494-502.
66. Sakamoto S, McCann RO, Dhir R, Kyprianou N, (2010) Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res 70: 1885-1895.
67. Kanamori H, Kawakami T, Effendi K, Yamazaki K, Mori T, et al. (2011) Identification by differential tissue proteome analysis of talin-1 as a novel molecular marker of progression of hepatocellular carcinoma. Oncology 80: 406-415.
68. Sansing HA, Sarkeshik A, Yates JR, Patel V, Gutkind JS, et al. (2011) Integrin alphabeta1, alphavbeta, alpha6beta effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance. Biochem Biophys Res Commun 406: 171-176.
69. Ichikawa T, Sato F, Terasawa K, Tsuchiya S, Toi M, et al. (2012) Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells. PLoS One 7: e31422.